The life sciences sector is capital-intensive, risky, and highly regulated. It is little surprise to find that innovation is dominated by large incumbent firms from Western markets. However, it is possible for emerging markets to become life sciences innovators. Emerging markets have gained ground over the past three decades, becoming innovators in their own right. India, China, Brazil, South Korea, Costa Rica and Singapore all found a life sciences niche in a relatively short space of time in areas such as biologics, medical technology and health informatics.
Innovation in life sciences
Adam Green
Senior editor, EMEA
Adam is a senior editor for The Economist Intelligence Unit's thought leadership division in EMEA, focusing primarily on the Middle East and Africa. In this role, he has worked on in-depth research studies, surveys, multimedia documentaries and infographics on topics ranging from healthcare to personal finance. Previously, Adam was Deputy Editor of This is Africa, a bimonthly magazine published by the Financial Times. He also worked as Communications Officer for the International Growth Centre, a research institute based at the London School of Economics and funded by the UK Department for International Development. Adam holds a Masters in Development Studies from the School of Oriental and African Studies, with a grade of distinction, and an undergraduate degree in Philosophy and History and Philosophy of Science from the University of Leeds. His independent research and journalism has been published by the Middle East Institute.
Related content
Health
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Health
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.
Health
The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.